Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529112 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01529112 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 135 participants.
The verdict
NCT01529112, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.
Interventions
- DRUG Lenvatinib
- DRUG Lenvatinib matched placebo
- DRUG BSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529112
The ClinicalTrials.gov registry entry for NCT01529112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenvatinib is the first listed.
NCT01529112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529112 about?
NCT01529112 is a clinical study titled "A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments". The purpose of this study is to compare the overall survival of patients receiving E7080 + Best Supportive Care (BSC) with those receiving placebo + Best Supportive Care.
What is the current status of trial NCT01529112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2011-11. Estimated completion is 2015-06-27.
What interventions are being tested in trial NCT01529112?
The interventions under investigation include: Lenvatinib (DRUG), Lenvatinib matched placebo (DRUG), BSC (DRUG).
Who is sponsoring clinical trial NCT01529112?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.